Targeting the Root of gMG With Inebilizumab: A Q&A With Richard Nowak, MD, MSJune 24th 2025
In this interview, Richard J. Nowak, MD, MS, principal investigator of the MINT trial of inebilizumab for generalized myasthenia gravis (gMG), discusses the trial’s key findings, including significant improvements in patient- and physician-assessed outcomes, as well as longer-term implications and future areas of investigation.